Propanc Biopharma Stock Today
| PPCB Stock | USD 25.00 13.00 108.33% |
Performance9 of 100
| Odds Of DistressOver 73
|
Propanc Biopharma is trading at 25.00 as of the 31st of January 2025, a 108.33 percent increase since the beginning of the trading day. The stock's open price was 12.0. Propanc Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of February 2023 and ending today, the 31st of January 2025. Click here to learn more.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 1.76 B outstanding shares. More on Propanc Biopharma
Moving against Propanc Pink Sheet
Propanc Pink Sheet Highlights
| CEO | James Nathanielsz |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Propanc Biopharma [PPCB] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 705.56 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Propanc Biopharma's market, we take the total number of its shares issued and multiply it by Propanc Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Propanc Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.76 B outstanding shares.
Propanc Biopharma currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations.
Check Propanc Biopharma Probability Of Bankruptcy
Ownership AllocationPropanc Biopharma owns a total of 1.76 Billion outstanding shares. Roughly 98.4 pct. of Propanc Biopharma outstanding shares are held by general public with 1.6 % owned by insiders and only 0.0 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Propanc Ownership Details
Propanc Biopharma Risk Profiles
| Mean Deviation | 16.46 | |||
| Semi Deviation | 13.77 | |||
| Standard Deviation | 25.38 | |||
| Variance | 644.28 |
Propanc Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Propanc Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.